Brief: Rafael Pharmaceuticals Crosses Midpoint Of Enrollment To First Interim Analysis In Phase 3 Trial Of Cpi-613 For Relapsed Or Refractory Acute Myeloid Leukemia

Rafael Holdings

21/07/2020 14:21

July 21 (Reuters) - Rafael Holdings Inc  RFL.N :
    * RAFAEL PHARMACEUTICALS CROSSES MIDPOINT OF ENROLLMENT TO
FIRST
INTERIM ANALYSIS IN PIVOTAL PHASE 3 TRIAL (ARMADA 2000) OF
CPI-613® (DEVIMISTAT) FOR RELAPSED OR REFRACTORY ACUTE MYELOID
LEUKEMIA (AML)

Source text for Eikon:  ID:nGNX72GGL6 
Further company coverage:  RFL.N 

 ((Reuters.Briefs@thomsonreuters.com;))